FDA Inspection 1166306 — RenovoRx, Inc.

RenovoRx, Inc. — FEI 3011279674

The FDA completed an inspection of RenovoRx, Inc. on Apr 4, 2022 in Mountain View, CA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 1 citation was issued during this inspection. Product area: Devices.

Inspection details

Classification
Voluntary Action Indicated (VAI)
End Date
Apr 4, 2022
Fiscal Year
2022
Product Type
Devices
Project Area
Postmarket Assurance: Devices
Location
Mountain View, CA (United States)

Citations

IDCFRDescription
73121 CFR 803.50(a)(1)Report of Death or Serious Injury

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.